Core Viewpoint - 111, Inc. is set to report its unaudited financial results for the fourth quarter and fiscal year 2024 on March 20, 2025, indicating a focus on transparency and communication with investors [1]. Company Overview - 111, Inc. is a leading tech-enabled healthcare platform in China, aiming to reshape the healthcare value chain by digitally empowering both upstream and downstream sectors [4]. - The company provides consumers with improved access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and its offline virtual pharmacy network [4]. - 111, Inc. also offers online healthcare services via its internet hospital, 1 Clinic, which includes online consultations, electronic prescriptions, and patient management services [4]. - The company operates 1 Medicine, an online platform that serves as a one-stop shop for pharmacies to source a wide range of pharmaceutical products [4]. - With the largest virtual pharmacy network in China, 111, Inc. enhances the ability of offline pharmacies to serve customers through cloud-based services [4]. - The company provides an omni-channel drug commercialization platform to strategic partners, offering services such as digital marketing, patient education, data analytics, and pricing monitoring [4]. Earnings Conference Call - The management team will host an earnings conference call on March 20, 2025, at 7:30 AM U.S. Eastern Time, allowing stakeholders to engage directly with the company's financial performance [2]. - Participants must register in advance to receive dial-in information, ensuring organized communication during the call [2][3]. - A live and archived webcast of the conference call will be available on the company's website, providing additional access to the information shared [3].

Core Viewpoint - 111, Inc. plans to change the ratio of its American Depositary Shares (ADSs) from one ADS representing two Class A ordinary shares to one ADS representing twenty Class A ordinary shares, effectively a one-for-ten reverse ADS split [1][2]. Company Overview - 111, Inc. is a leading tech-enabled healthcare platform in China, focused on reshaping the healthcare value chain by digitally empowering both upstream and downstream sectors [1][4]. - The company provides consumers with improved access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and its offline virtual pharmacy network [4]. - 111 also offers online healthcare services via its internet hospital, 1 Clinic, which includes online consultations, electronic prescriptions, and patient management services [4]. - The company operates the largest virtual pharmacy network in China, enabling offline pharmacies to enhance customer service through cloud-based solutions [4]. - Additionally, 111 provides an omni-channel drug commercialization platform that includes digital marketing, patient education, data analytics, and pricing monitoring for its strategic partners [4]. ADS Ratio Change Impact - The ratio change will not affect the underlying Class A ordinary shares, and no shares will be issued or cancelled as a result [2]. - The change is expected to take effect on January 24, 2025, and the ADS price is anticipated to increase proportionally, although no assurance can be given regarding the exact price post-change [2].

Financial Data and Key Metrics Changes - Total net revenues for Q3 2024 were RMB3.6 billion, remaining relatively flat compared to the same quarter of last year [51] - Gross segment profit grew 10.5% to RMB210.6 million, while total operating expenses decreased 23.2% to RMB28.2 million [51][52] - Income from operations was RMB2.4 million compared to a loss of RMB80.4 million in the same quarter last year, indicating a significant turnaround [20][53] - Non-GAAP income from operations was RMB7.1 million compared to a non-GAAP loss of RMB54 million in Q3 of the prior year [54] Business Line Data and Key Metrics Changes - Total operating expenses as a percentage of net revenues decreased to 5.8% from 7.4% year-over-year, reflecting enhanced operational efficiency [52] - Fulfillment expenses remained steady at 2.8% of net revenues, while selling expenses decreased to 2.1% from 2.6% in the prior year [52][21] - General and administrative expenses accounted for 0.4% of net revenues, down from 1.3% a year ago, showcasing effective cost management [52] Market Data and Key Metrics Changes - Retail pharmacy sales in China decreased by 2.2% in the first nine months of 2024, indicating a challenging market environment [11] - The per capita healthcare expenditures growth rate declined by 11.5 percentage points from a year earlier for the first nine months [9] Company Strategy and Development Direction - The company is focusing on digital transformation and operational efficiency to navigate the challenging macroeconomic environment [7][14] - There is a commitment to leveraging technology to reshape the value chain and enhance operational efficiency [61] - The company aims to capture growth opportunities in the out-of-hospital pharmaceutical distribution market, projected to reach RMB1.1 trillion in three years [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth of China's healthcare market, driven by an aging population and increased healthcare consumption [19][82] - The company anticipates achieving operational profitability for the entire year, reflecting confidence in its operational strategies [72] Other Important Information - The company reported positive operating cash flow for three consecutive quarters, indicating improved cash management [55][78] - The company has reached agreements with investors to reschedule repayments, allowing for phased repayment periods [56] Q&A Session Summary Question: Is there room for OpEx to further decrease and what measures will be taken? - Management confirmed that there is room for further reduction in OpEx, emphasizing the role of technology and smart staffing in achieving this [61][63] Question: What factors are driving the improvement in gross margin despite flat revenue? - Management highlighted assortment management and category management as key drivers for margin improvement, focusing on minimizing money-losing categories [66][68] Question: Will the company achieve operating profit for the entire year? - Management expressed optimism about achieving operational profitability for the entire year [72] Question: What improvements were made in supply chain management in Q3? - Management reported a decrease in order fulfillment costs and improvements in logistics and warehousing efficiency [73][75] Question: How has the company achieved positive operating cash flow for three consecutive quarters? - Management attributed positive cash flow to effective working capital control and improved turnover rates for inventory and accounts receivable [78]

Financial Performance - Net revenues for Q3 2024 were RMB3.6 billion (US$513.1 million), a decrease of 1.8% from RMB3.7 billion in the same quarter last year[5]. - Income from operations was RMB2.4 million (US$0.3 million), compared to a loss of RMB80.4 million in the same quarter last year, marking operational profitability for the third consecutive quarter[3][7]. - Gross segment profit increased by 10.5% year-over-year to RMB210.6 million (US$30.0 million)[3]. - Non-GAAP income from operations was RMB7.1 million (US$1.0 million), compared to a non-GAAP loss of RMB54.0 million in the same quarter last year[7]. - Net loss attributable to ordinary shareholders improved by 82% to RMB17.1 million (US$2.4 million), accounting for 0.5% of net revenues, down from 2.5% in the same quarter last year[9]. - The company reported a net loss of RMB 3,462 for the three months ended September 30, 2024, significantly improved from a net loss of RMB 83,478 in the same period of 2023[27]. - Non-GAAP net loss attributable to ordinary shareholders for the nine months ended September 30, 2024, was RMB 29,780 million, compared to RMB 107,509 million for the same period in 2023, indicating a reduction of approximately 72.3%[31]. - The loss per ADS for the three months ended September 30, 2024, improved to RMB 0.20 from RMB 1.10 in the same period of 2023[31]. - Non-GAAP loss per ADS for the nine months ended September 30, 2024, was RMB 0.34, down from RMB 1.28 in the same period of 2023, reflecting a 73.4% improvement[31]. - The total loss from operations for the three months ended September 30, 2024, was RMB 2,371 million, compared to a loss of RMB 80,422 million in the same period of 2023[31]. Operating Expenses and Cash Flow - Total operating expenses decreased by 23.2% year-over-year to RMB208.2 million (US$29.7 million), representing 5.8% of net revenues, down from 7.4% in the same quarter last year[3][5]. - The company achieved positive operating cash flow for three consecutive quarters, with net cash from operating activities at RMB109.9 million (US$15.7 million)[3]. - Fulfillment expenses were RMB100.0 million (US$14.2 million), a decrease of 1.6% from the same quarter last year, maintaining 2.8% of net revenues[11]. - Operating costs and expenses for the three months ended September 30, 2024, were RMB 3,598,304, a decrease from RMB 3,745,667 in the same period of 2023[27]. - The company generated RMB 109,865 in net cash from operating activities for the three months ended September 30, 2024, compared to RMB 35,208 in the same period of 2023[29]. - Share-based compensation expenses for the three months ended September 30, 2024, were RMB 4,756 million, down from RMB 26,402 million in the same period of 2023[31]. Assets and Liabilities - As of September 30, 2024, cash and cash equivalents totaled RMB614.4 million (US$87.6 million), down from RMB673.7 million at the end of 2023[11]. - Cash and cash equivalents, and restricted cash at the end of the period were RMB 564,411, down from RMB 766,218 at the beginning of the period[29]. - Total current assets increased slightly to RMB 2,886,888 as of September 30, 2024, compared to RMB 2,933,331 as of December 31, 2023[26]. - The company’s total liabilities were RMB 2,722,172 as of September 30, 2024, compared to RMB 2,812,932 as of December 31, 2023, indicating a reduction in liabilities[26]. - The company’s inventories decreased to RMB 1,532,170 as of September 30, 2024, from RMB 1,419,396 as of December 31, 2023[26]. Strategic Initiatives - The company is investing in AI and digital technologies to enhance operational efficiency and adapt to industry changes, focusing on digital transformation and out-of-hospital drug distribution[4]. - The company plans to continue expanding its online healthcare services and enhance its digital marketing capabilities to improve market competitiveness[22]. - 111, Inc. aims to maintain compliance with Nasdaq listing criteria and manage growth effectively amid evolving regulatory requirements[21]. - The company aims to continue improving its financial performance and reducing losses in the upcoming quarters[31].

Core Viewpoint - 111, Inc. has maintained operational profitability for the third consecutive quarter, demonstrating improved operational efficiency despite a challenging macroeconomic environment in China [1][4]. Financial Performance - Net revenues for Q3 2024 were RMB 3.6 billion (US$ 513.1 million), showing a slight decrease of 1.8% from RMB 3.7 billion in the same quarter last year [2][5]. - Gross segment profit increased by 10.5% year-over-year to RMB 210.6 million (US$ 30.0 million) [2]. - Total operating expenses decreased by 23.2% to RMB 208.2 million (US$ 29.7 million) from RMB 271.0 million in the same quarter last year, with operating expenses as a percentage of net revenues dropping by 160 basis points to 5.8% [2][4]. - Income from operations was RMB 2.4 million (US$ 0.3 million), a significant improvement from a loss of RMB 80.4 million in the same quarter last year [2][9]. - Non-GAAP income from operations was RMB 7.1 million (US$ 1.0 million), compared to a non-GAAP loss of RMB 54.0 million in the same quarter last year [2][10]. Cash Flow and Expenses - The company achieved positive operating cash flow for three consecutive quarters, with net cash from operating activities amounting to RMB 109.9 million (US$ 15.7 million) [2][30]. - Fulfillment expenses were RMB 100.0 million (US$ 14.2 million), a decrease of 1.6% from RMB 101.6 million in the same quarter last year [8]. - Selling and marketing expenses decreased by 19.4% to RMB 77.0 million (US$ 11.0 million) [8]. Strategic Initiatives - The company is focused on enhancing operational efficiency through cost management, infrastructure investments, and effective staffing arrangements [4]. - Investments in AI and digital technologies are aimed at reshaping the healthcare value chain and capturing shifts in the pharmaceutical industry [4]. - The company is expanding its fulfillment network and refining digital platforms to strengthen core competitiveness in digitalization [4]. Balance Sheet and Liabilities - As of September 30, 2024, the company had cash and cash equivalents of RMB 614.4 million (US$ 87.6 million), down from RMB 673.7 million at the end of 2023 [14]. - The total outstanding amount owed to investors was RMB 1.1 billion, with agreements reached to reschedule repayments for approximately 90% of this amount [14].

Core Viewpoint - 111, Inc. is set to participate in a fireside chat discussing its Q3 2024 earnings, challenges, opportunities, and NASDAQ share price compliance issue on December 6, 2024 [1][2]. Company Overview - 111, Inc. is a leading tech-enabled healthcare platform in China, focused on reshaping the healthcare value chain by digitally empowering both upstream and downstream sectors [5]. - The company provides consumers with improved access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and an offline virtual pharmacy network [5]. - It also offers online healthcare services via its internet hospital, 1 Clinic, which includes online consultations, electronic prescriptions, and patient management services [5]. - 111 operates the largest virtual pharmacy network in China, enabling offline pharmacies to enhance customer service through cloud-based solutions [5]. - The company provides an omni-channel drug commercialization platform, offering services such as digital marketing, patient education, data analytics, and pricing monitoring to its strategic partners [5]. Upcoming Events - The fireside chat will feature Mr. Junling Liu, Co-Founder, Chairman, and CEO of 111, discussing the company's upcoming Q3 2024 earnings report scheduled for November 27, 2024 [2]. - Registration for the event is available through a designated link, and a replay will be accessible on the company's investor relations website [3].

Core Viewpoint - 111, Inc. is set to release its unaudited financial results for Q3 2024 earlier than previously scheduled, now on November 27, 2024, before U.S. market opens [1] Group 1: Financial Results Announcement - The release of unaudited financial results for the third quarter ended September 30, 2024, will occur before the U.S. market opens on November 27, 2024, instead of November 28, 2024 [1] - An earnings conference call will be hosted by the management team at 7:30 AM U.S. Eastern Time on November 27, 2024 [2] Group 2: Conference Call Details - Participants must register online in advance to receive dial-in information, including the passcode and unique access PIN [2] - A live and archived webcast of the conference call will be available on the company's website [3] - A telephone replay of the call will be accessible until December 4, 2024 [3] Group 3: Company Overview - 111, Inc. is a leading tech-enabled healthcare platform in China, focused on reshaping the healthcare value chain by digitally empowering both upstream and downstream sectors [4] - The company provides better access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and its offline virtual pharmacy network [4] - Online healthcare services are offered through its internet hospital, 1 Clinic, which includes online consultations and electronic prescriptions [4] - The company operates the largest virtual pharmacy network in China, enabling offline pharmacies to enhance customer service with cloud-based solutions [4] - 111, Inc. also provides an omni-channel drug commercialization platform, offering services like digital marketing and data analytics to strategic partners [4]

Core Viewpoint - 111, Inc. announced the resignation of Dr. Leon Lian Yong Chen from its board of directors and the appointment of Mr. Yang "Luke" Chen as a new director, effective November 4, 2024, highlighting a transition in leadership that aims to strengthen the company's strategic initiatives in the healthcare sector [1][2][3]. Group 1: Leadership Changes - Dr. Leon Lian Yong Chen has served on the board since May 2019 and has made significant contributions to the company's goals and strategies [2]. - Mr. Yang "Luke" Chen, currently the Senior Finance Executive, has been appointed as a new director, bringing extensive financial expertise and a deep understanding of the business [3]. Group 2: Company Overview - 111, Inc. is a tech-enabled healthcare platform in China, focused on reshaping the healthcare value chain by digitally empowering both upstream and downstream sectors [4]. - The company provides better access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and its offline virtual pharmacy network [4]. - 111, Inc. also offers online healthcare services via its internet hospital, 1 Clinic, which includes online consultations and electronic prescriptions [4].

SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Wednesday, October 30, 2024 at 12:00 p.m. ET.Dr. Gang Yu, Co-Founder and Executive Chairman of 111, will dis ...

SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, before the U.S. market opens on Thursday, November 28, 2024.111's management team will host an earnings conference call at 7:30 AM U ...